Breaking News, Collaborations & Alliances

Hikma Partners with Emergent for the Sale of KLOXXADO in the U.S. & Canada

Emergent will add KLOXXADO Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.

Author Image

By: Charlie Sternberg

Associate Editor

Hikma Pharmaceuticals PLC, the multinational pharmaceutical group, has entered an exclusive commercial partnership with Emergent BioSolutions for the sale of KLOXXADO naloxone HCl nasal spray 8 mg in the U.S. and Canada. KLOXXADO was approved by the US Food and Drug Administration (FDA) in April 2021 for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.  Emergent distribu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters